Polymers for reversing heparin-based anticoagulation
US-2015224244-A1 · Aug 13, 2015 · US
US10111902B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10111902-B2 |
| Application number | US-201514629408-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 23, 2015 |
| Priority date | Jun 1, 2011 |
| Publication date | Oct 30, 2018 |
| Grant date | Oct 30, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules.
Opening claim text (preview).
The invention claimed is: 1. A controlled release delivery device comprising: a support having a surface; a heparin binding polymer attached to the surface, the heparin binding polymer comprising: a first dendritic polyol; one or more cationic moieties, at least one of the one or more cationic moieties attached to the first dendritic polyol; and at least one cleavage site; and heparin bound to the heparin binding polymer, wherein the heparin binding polymer has the structure of Formula (I): wherein L1, L2, L3, L4 and L5 comprise dendritic polyols. 2. The controlled release delivery device of claim 1 , wherein the surface forms part of a bead. 3. The controlled release delivery device of claim 1 , wherein the surface comprises a flat surface. 4. The controlled release delivery device of claim 1 , wherein the surface forms at least a portion of a cartridge. 5. The controlled release delivery device of claim 1 , wherein the heparin binding polymer is attached to the surface via an acetal bond or a ketal bond. 6. The controlled release delivery device of claim 1 , wherein the heparin binding polymer is attached to the surface via a disulfide bond. 7. The controlled release delivery device of claim 1 , wherein the heparin binding polymer comprises a protective moiety covalently attached to the first dendritic polyol. 8. The controlled release delivery device of claim 1 , wherein the heparin binding polymer comprises a second dendritic polyol, wherein the at least one cleavage site links the first dendritic polyol to the second dendritic polyol. 9. A controlled release delivery device comprising: a support having a surface; a heparin binding polymer attached to the surface, the heparin binding polymer comprising: a first dendritic polyol; one or more cationic moieties, at least one of the one or more cationic moieties attached to the first dendritic polyol; and at least one cleavage site; and heparin bound to the heparin binding polymer, wherein the heparin binding polymer has the structure of Formula (II): wherein L1, L2, L3, and L4 comprise dendritic polyols. 10. The controlled release delivery device of claim 9 , wherein the surface forms part of a bead. 11. The controlled release delivery device of claim 9 , wherein the surface comprises a flat surface. 12. The controlled release delivery device of claim 9 , wherein the surface forms at least a portion of a cartridge. 13. The controlled release delivery device of claim 9 , wherein the heparin binding polymer is attached to the surface via an acetal bond or a ketal bond. 14. The controlled release delivery device of claim 9 , wherein the heparin binding polymer comprises a protective moiety covalently attached to the first dendritic polyol. 15. The controlled release delivery device of claim 9 , wherein the heparin binding polymer comprises a second dendritic polyol, wherein the at least one cleavage site links the first dendritic polyol to the second dendritic polyol.
Polymers containing nitrogen · CPC title
Blood · CPC title
Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title
Polyalkylene oxides · CPC title
Polyamines containing oxygen in the form of ether bonds in the main chain · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.